Navigation Links
Mayo Clinic gets FDA approval for new imaging agent for recurrent prostate cancer
Date:11/8/2012

ROCHESTER, Minn. -- Mayo Clinic has received U.S. Food and Drug Administration approval to produce and administer Choline C 11 Injection, an imaging agent used during a positron emission tomography (PET) scan to help detect sites of recurrent prostate cancer. Mayo Clinic is the first, and currently only, institution in North America approved to produce this imaging agent.

VIDEO ALERT: Video interviews and animation are available for journalists to download on the Mayo Clinic News Network.

Choline C 11 Injection is a radioactive form of the vitamin choline. Clinicians inject a small amount of the agent into a patient's vein and then use a PET scanner and computer to make detailed pictures of areas where the agent collects. Since cancer cells take up more Choline C 11 than do normal cells, the pictures can be used to help find areas of possible cancer in the body when bone scintigraphy, computerized tomography or magnetic resonance imaging is non-informative. Once a site is identified, a biopsy and pathologic examination can verify whether prostate cancer has recurred.

Evaluating men for prostate cancer recurrence has long been a major challenge; physicians have had to wait until a patient's prostate-specific antigen (PSA) levels rose to values between 20-30 ng/mL to identify sites of recurrent prostate cancer.

"This technology is a game changer," says Eugene Kwon, M.D., a urologist at Mayo Clinic. "In stark contrast to conventional imaging, PET imaging with Choline C 11 Injection can help identify sites of recurrence for tissue sampling and examination when a patient's PSA level reaches

2 ng/mL months or even years earlier than before. This technology also allows us to pinpoint the locations of recurrent cancer more accurately and permits us to develop more effective treatment strategies."

About 90,000 men annually seek treatment for recurrent prostate cancer, according to the Surveillance, Epidemiology and End Results database. Recurrent prostate cancer is defined as cancer that has recurred following initial therapy, which could include surgery, radiation therapy, hormone therapy or chemotherapy.

Choline C 11 Injection has a short shelf life and must be made in a specialized facility and given to patients within minutes after production. Mayo Clinic has the integrated production, imaging and pathology facilities to provide the benefit of Choline C 11 PET imaging to patients.

Choline C 11 Injection is a perfect fit for Mayo because its urologists see some of the most complex cases of recurrent prostate cancer in the country, Dr. Kwon says. He cautions that even with its advantage over conventional imaging, PET imaging with Choline C 11 injection is not a replacement for a tissue biopsy and histologic verification of recurrent prostate cancer.

"We worked very closely with the FDA to obtain approval to administer this agent," says Val Lowe, M.D., a radiologist at Mayo Clinic who worked on the new drug application. "The FDA understood our needs as an academic institution trying to bring novel technology to the clinician and they were very responsive."

The safety and effectiveness of Choline C 11 Injection were verified by a systematic review of published study reports.

Possible allergic reactions and mild injection site reactions may occur with the use of Choline C 11 Injection. However, no adverse reactions to Choline C 11 Injection have been reported other than a mild injection site reaction. Choline C 11 Injection contributes to a patient's long-term cumulative radiation exposure. Imaging errors have been reported; in particular, blood PSA levels < 2ng/ml have been associated with poor imaging performance.


'/>"/>

Contact: Joe Dangor
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
Source:Eurekalert

Related medicine news :

1. Lower GI problems plague many with rheumatoid arthritis, Mayo Clinic study finds
2. First targeted nanomedicine to enter human clinical studies
3. Clinical insight improves treatment with new lung cancer drug
4. Clinical news alert from the American Academy of Orthopaedic Surgeons
5. Mayo Clinic launches whole genome breast cancer study
6. Mayo Clinic offers newly approved treatment for acid reflux disease
7. NYU Langone experts present research, clinical advances at neurosurgeons meeting
8. Mayo Clinic breast cancer study finds new type of mutation
9. Kroenke honored for outstanding contributions in clinical research training
10. Awards celebrate clinical research that can improve health and alleviate suffering
11. Association for Psychological Science, SAGE launch Clinical Psychological Science
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... ... March is National Kidney Month – the perfect time to pause and thank ... Every day, two kidneys filter about 120 to 150 quarts of blood. Put another ... regulating fluid levels and blood pressure, supporting bone health and promoting red blood cell ...
(Date:3/23/2017)... ... March 23, 2017 , ... The StayWell Company announced ... The accreditation covers StayWell’s asthma, coronary artery disease, congestive heart failure, chronic obstructive ... that have excellent programs for the delivery and improvement of disease management and ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... ... educational training program owned and organized by HMP Communications Holdings, LLC, today announced ... for physicians within its nationwide network of wound centers interested in becoming Certified ...
(Date:3/23/2017)... CO (PRWEB) , ... March 23, 2017 , ... ... serving the families and businesses of the greater Fort Collins area, has unveiled ... in their ongoing community involvement program. Donations to this worthy cause may now ...
(Date:3/23/2017)... ... , ... After raising more than $1.135 million ($1,479,231 AUD) from nearly 20,000 ... in crowdfunding history, has established a U.S. Headquarters in New York City, FaceCradle USA, ... “We’re excited to be operating on U.S. shores, where most of our initial crowdfunding ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... , March 23, 2017  The U.S. Food ... (avelumab) for the treatment of adults and pediatric patients ... (MCC), including those who have not received prior chemotherapy. ... a rare, aggressive form of skin cancer. ... cancers, patients with a rare form called Merkel cell ...
(Date:3/23/2017)... DIEGO and VANCOUVER, British Columbia ... (NASDAQ: SPHS ) (the "Company" or "Sophiris"), ... the treatment of urological diseases, today announced that data ... evaluated the drug as a focal treatment for localized ... March 26, 2017 at the 32 nd Annual ...
(Date:3/23/2017)... , Mar. 23, 2017 Research and ... Devices Market 2017-2021" report to their offering. ... The global oxygen therapy devices ... 2017-2021. The report, Global Oxygen Therapy Devices Market ... inputs from industry experts. The report covers the market landscape and ...
Breaking Medicine Technology: